Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-06-30 View official record Methodology

Covered recipient · General Payments record

IMELDA R MIRANDA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1578510681
CMS profile
161578
Location
UPPER MARLBORO, MD

General Payments · PY2019–2025

$6,855.11

  • Reported across 362 records
  • CMS publication 2026-06-30

Latest program year · PY2025

$288.29

14 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2025 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $288.29 14

By paying entity

PY2025 · sorted by reported total

Paying entityAmountRecords
Novo Nordisk AS $74.06 3
Lilly USA, LLC $53.69 3
Exact Sciences Corporation $51.58 2
Acerta Pharma LLC $33.40 2
Abbott Laboratories $23.63 1
Astellas Pharma US Inc $21.21 1
Globus Medical, Inc. $17.21 1
GlaxoSmithKline, LLC. $13.51 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,437.23 83
PY2020 $1,165.66 59
PY2021 $1,339.07 72
PY2022 $1,227.71 62
PY2023 $770.78 41
PY2024 $626.37 31
PY2025 $288.29 14

Payment records · PY2025 (14)

Sorted by paying entity, then date · as published by CMS

Program year 2025 201920202021202220232024 Record-level detail is published for PY2025; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Abbott Laboratories $23.63 01/28/2025 Food and Beverage Undisputed 06/30/2026 1240899998 CMS
Astellas Pharma US Inc $21.21 09/27/2025 Food and Beverage Undisputed 06/30/2026 1238690914 CMS
AstraZeneca Pharmaceuticals LP $16.30 01/24/2025 Food and Beverage Undisputed 06/30/2026 1206679672 CMS
AstraZeneca Pharmaceuticals LP $17.10 01/28/2025 Food and Beverage Undisputed 06/30/2026 1207286854 CMS
Exact Sciences Corporation $28.06 03/24/2025 Food and Beverage Undisputed 06/30/2026 1235531807 CMS
Exact Sciences Corporation $23.52 06/03/2025 Food and Beverage Undisputed 06/30/2026 1235531811 CMS
GlaxoSmithKline, LLC. $13.51 05/28/2025 Food and Beverage Undisputed 06/30/2026 1190939604 CMS
Globus Medical, Inc. $17.21 03/31/2025 Food and Beverage Undisputed 06/30/2026 1250081143 CMS
Lilly USA, LLC $22.06 03/13/2025 Food and Beverage Undisputed 06/30/2026 1186639207 CMS
Lilly USA, LLC $17.60 10/09/2025 Food and Beverage Undisputed 06/30/2026 1186615360 CMS
Lilly USA, LLC $14.03 10/09/2025 Food and Beverage Undisputed 06/30/2026 1186653949 CMS
Novo Nordisk Inc $27.53 03/18/2025 Food and Beverage Undisputed 06/30/2026 1188506925 CMS
Novo Nordisk Inc $22.83 04/03/2025 Food and Beverage Undisputed 06/30/2026 1188828414 CMS
Novo Nordisk Inc $23.70 10/17/2025 Food and Beverage Undisputed 06/30/2026 1188303298 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.